BR112018074355A2 - composição de probióticos e enzimas digestivas e método de preparação e uso do mesmo - Google Patents
composição de probióticos e enzimas digestivas e método de preparação e uso do mesmoInfo
- Publication number
- BR112018074355A2 BR112018074355A2 BR112018074355-0A BR112018074355A BR112018074355A2 BR 112018074355 A2 BR112018074355 A2 BR 112018074355A2 BR 112018074355 A BR112018074355 A BR 112018074355A BR 112018074355 A2 BR112018074355 A2 BR 112018074355A2
- Authority
- BR
- Brazil
- Prior art keywords
- mammal
- blood
- lactobacillus
- probiotics
- ldl
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000006041 probiotic Substances 0.000 title abstract 3
- 235000018291 probiotics Nutrition 0.000 title abstract 3
- 102000038379 digestive enzymes Human genes 0.000 title abstract 2
- 108091007734 digestive enzymes Proteins 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 5
- 239000008280 blood Substances 0.000 abstract 5
- 210000004369 blood Anatomy 0.000 abstract 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 4
- 239000004365 Protease Substances 0.000 abstract 2
- 230000002708 enhancing effect Effects 0.000 abstract 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 2
- 239000004382 Amylase Substances 0.000 abstract 1
- 108010065511 Amylases Proteins 0.000 abstract 1
- 102000013142 Amylases Human genes 0.000 abstract 1
- 102100026189 Beta-galactosidase Human genes 0.000 abstract 1
- 241000186000 Bifidobacterium Species 0.000 abstract 1
- 241000186016 Bifidobacterium bifidum Species 0.000 abstract 1
- 108010004032 Bromelains Proteins 0.000 abstract 1
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 abstract 1
- 102100022624 Glucoamylase Human genes 0.000 abstract 1
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract 1
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract 1
- 102000007330 LDL Lipoproteins Human genes 0.000 abstract 1
- 108010007622 LDL Lipoproteins Proteins 0.000 abstract 1
- 108010059881 Lactase Proteins 0.000 abstract 1
- 240000001046 Lactobacillus acidophilus Species 0.000 abstract 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 abstract 1
- 244000199866 Lactobacillus casei Species 0.000 abstract 1
- 235000013958 Lactobacillus casei Nutrition 0.000 abstract 1
- 241000186605 Lactobacillus paracasei Species 0.000 abstract 1
- 240000006024 Lactobacillus plantarum Species 0.000 abstract 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 abstract 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 abstract 1
- 241000186869 Lactobacillus salivarius Species 0.000 abstract 1
- 239000004367 Lipase Substances 0.000 abstract 1
- 102000004882 Lipase Human genes 0.000 abstract 1
- 108090001060 Lipase Proteins 0.000 abstract 1
- 108090000526 Papain Proteins 0.000 abstract 1
- 108010028144 alpha-Glucosidases Proteins 0.000 abstract 1
- 102000016679 alpha-Glucosidases Human genes 0.000 abstract 1
- 235000019418 amylase Nutrition 0.000 abstract 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 abstract 1
- 108010005774 beta-Galactosidase Proteins 0.000 abstract 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 abstract 1
- 235000019835 bromelain Nutrition 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 230000036996 cardiovascular health Effects 0.000 abstract 1
- 229940088598 enzyme Drugs 0.000 abstract 1
- 229940059442 hemicellulase Drugs 0.000 abstract 1
- 108010002430 hemicellulase Proteins 0.000 abstract 1
- 239000001573 invertase Substances 0.000 abstract 1
- 235000011073 invertase Nutrition 0.000 abstract 1
- 229940116108 lactase Drugs 0.000 abstract 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 abstract 1
- 229940017800 lactobacillus casei Drugs 0.000 abstract 1
- 229940072205 lactobacillus plantarum Drugs 0.000 abstract 1
- 235000019421 lipase Nutrition 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 229940055729 papain Drugs 0.000 abstract 1
- 235000019834 papain Nutrition 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01001—Alpha-amylase (3.2.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01003—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01004—Cellulase (3.2.1.4), i.e. endo-1,4-beta-glucanase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01008—Endo-1,4-beta-xylanase (3.2.1.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01026—Beta-fructofuranosidase (3.2.1.26), i.e. invertase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01108—Lactase (3.2.1.108)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22002—Papain (3.4.22.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22032—Stem bromelain (3.4.22.32)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2016/033976 WO2017204788A1 (en) | 2016-05-24 | 2016-05-24 | Composition of probiotics and digestive enzymes and method of preparing and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018074355A2 true BR112018074355A2 (pt) | 2019-03-06 |
Family
ID=60411761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018074355-0A BR112018074355A2 (pt) | 2016-05-24 | 2016-05-24 | composição de probióticos e enzimas digestivas e método de preparação e uso do mesmo |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200323929A1 (https=) |
| EP (1) | EP3463404A4 (https=) |
| JP (1) | JP2019516775A (https=) |
| KR (1) | KR102380198B1 (https=) |
| CN (1) | CN109451727A (https=) |
| AU (1) | AU2016408376B2 (https=) |
| BR (1) | BR112018074355A2 (https=) |
| CA (1) | CA3025512A1 (https=) |
| IL (1) | IL263238A (https=) |
| MX (1) | MX2018014500A (https=) |
| RU (1) | RU2018144897A (https=) |
| WO (1) | WO2017204788A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3055915A1 (en) * | 2017-03-10 | 2018-09-13 | Biohm Health Llc | Compositions and methods for disrupting biofilms of pathogenic bacteria or fungi |
| WO2019169179A1 (en) * | 2018-02-28 | 2019-09-06 | Shafer Kim | Augmenting efficacy of cancer therapies using probiotic based compositions |
| US20210030818A1 (en) * | 2018-03-09 | 2021-02-04 | Biohm Health Llc | Compositions for use in balancing microbiome |
| CN109528776A (zh) * | 2018-06-08 | 2019-03-29 | 广东益可维健康科技有限公司 | 一种预防治疗口腔疾病的复合益生菌含片及其制备方法 |
| CN109566935A (zh) * | 2018-12-06 | 2019-04-05 | 张秋环 | 综合益生菌复合粉固体饮料的制备方法 |
| TWI740101B (zh) * | 2019-02-12 | 2021-09-21 | 大江生醫股份有限公司 | 降膽固醇之益生菌株的用途 |
| KR102119133B1 (ko) | 2019-05-02 | 2020-06-26 | 선정완 | 유산균 분말 및 노니 분말을 포함하는 프로바이오틱스 조성물 |
| KR102124474B1 (ko) * | 2019-08-30 | 2020-06-19 | 주식회사 에이치이엠 | Pmas방법을 이용한 개인 맞춤형 장내 환경 개선 물질 스크리닝 방법 |
| ES3013459T3 (en) | 2019-08-30 | 2025-04-14 | Hem Pharma Inc | Method for screening personalized gut environment-improving substance using pmas process |
| KR102335928B1 (ko) * | 2019-10-02 | 2021-12-08 | 한국생명공학연구원 | 비만의 예방, 치료 또는 개선용 조성물 |
| CN111213885A (zh) * | 2020-01-20 | 2020-06-02 | 齐海心 | 一种具有调节血脂功效的益生菌组合物及其制备方法与应用 |
| TW202203950A (zh) * | 2020-03-30 | 2022-02-01 | 香港商香港微生物菌群創新中心有限公司 | 微生物在調節體重和膽固醇水準中的用途 |
| CN111558033A (zh) * | 2020-05-14 | 2020-08-21 | 广州中昱医学生物科技有限公司 | 一种口腔清洁组合物及其应用 |
| CN112021575A (zh) * | 2020-09-17 | 2020-12-04 | 泉州亚林新材料科技有限公司 | 一种益生菌组合物及其制备方法 |
| KR20230156825A (ko) * | 2021-01-19 | 2023-11-14 | 에이티알 쓰라이브 엘엘씨 | 성인 영양을 위한 우유와 효소의 조성물 |
| CN113244408A (zh) * | 2021-06-02 | 2021-08-13 | 河北源民生物科技有限公司 | 一种适用于肠胃的益生菌组合物 |
| JP2023159522A (ja) * | 2022-04-20 | 2023-11-01 | 国立大学法人 和歌山大学 | 短鎖脂肪酸産生促進用組成物 |
| CN115025132B (zh) * | 2022-06-09 | 2024-01-30 | 康永波 | 一种合生元组合物及其制备方法和应用 |
| CN116042486B (zh) * | 2023-02-22 | 2024-11-08 | 高邮市人民医院 | 一种用于治疗动脉粥样硬化的复合菌制剂 |
| WO2025076281A1 (en) * | 2023-10-06 | 2025-04-10 | Biohm Health Inc. | Microbiome modulating formula for menopausal-aged women |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7432097B2 (en) * | 1997-08-13 | 2008-10-07 | Verenium Corporation | Phytases, nucleic acids encoding them and methods of making and using them |
| US6436451B1 (en) * | 1999-03-26 | 2002-08-20 | Eggland's Best, Inc. | Method of reducing cholesterol in chicken eggs |
| US6368617B1 (en) * | 2001-05-15 | 2002-04-09 | Reliv' International, Inc. | Dietary supplement |
| US20040071685A1 (en) * | 2002-10-09 | 2004-04-15 | Devin Houston | Compositions and methods for increasing the bioavailability of plant polyphenols |
| GB2465814B (en) * | 2008-06-19 | 2011-10-26 | Tarig Sayed Mustafa Arbab | Method,composition and device for the treatment of enzymes and saccharides disorders |
| US8257694B2 (en) * | 2009-05-14 | 2012-09-04 | Product Partners, Llc | Nutritional compositions for reducing oxidative damage |
| BR112012024674B1 (pt) * | 2010-04-26 | 2019-07-02 | Novozymes A/S | Grânulo, e, composição de detergente granular |
| US9301983B2 (en) * | 2014-03-07 | 2016-04-05 | Genmont Biotech Inc. | Composition and method of Lactobacillus reuteri GMNL-89 in treating type 2 diabetes |
| WO2015172191A1 (en) * | 2014-05-12 | 2015-11-19 | Medlab Ip Pty Ltd | Probiotic compositions and uses thereof for treatment of obesity-related disorders |
| AU2015100952A4 (en) * | 2014-07-17 | 2015-08-20 | Pharm-A-Care Laboratories Pty Ltd | Probiotic- and enzyme-containing compositions and uses thereof |
-
2016
- 2016-05-24 RU RU2018144897A patent/RU2018144897A/ru not_active Application Discontinuation
- 2016-05-24 WO PCT/US2016/033976 patent/WO2017204788A1/en not_active Ceased
- 2016-05-24 MX MX2018014500A patent/MX2018014500A/es unknown
- 2016-05-24 AU AU2016408376A patent/AU2016408376B2/en not_active Ceased
- 2016-05-24 BR BR112018074355-0A patent/BR112018074355A2/pt not_active Application Discontinuation
- 2016-05-24 CN CN201680086942.3A patent/CN109451727A/zh active Pending
- 2016-05-24 JP JP2018562173A patent/JP2019516775A/ja not_active Ceased
- 2016-05-24 US US16/304,123 patent/US20200323929A1/en not_active Abandoned
- 2016-05-24 CA CA3025512A patent/CA3025512A1/en not_active Abandoned
- 2016-05-24 KR KR1020187037308A patent/KR102380198B1/ko active Active
- 2016-05-24 EP EP16903312.3A patent/EP3463404A4/en not_active Withdrawn
-
2018
- 2018-11-22 IL IL263238A patent/IL263238A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN109451727A (zh) | 2019-03-08 |
| IL263238A (en) | 2018-12-31 |
| RU2018144897A3 (https=) | 2020-06-25 |
| AU2016408376B2 (en) | 2020-10-22 |
| KR102380198B1 (ko) | 2022-03-29 |
| AU2016408376A1 (en) | 2019-01-17 |
| WO2017204788A1 (en) | 2017-11-30 |
| JP2019516775A (ja) | 2019-06-20 |
| CA3025512A1 (en) | 2017-11-30 |
| EP3463404A4 (en) | 2020-03-11 |
| KR20190015718A (ko) | 2019-02-14 |
| US20200323929A1 (en) | 2020-10-15 |
| RU2018144897A (ru) | 2020-06-25 |
| EP3463404A1 (en) | 2019-04-10 |
| MX2018014500A (es) | 2019-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018074355A2 (pt) | composição de probióticos e enzimas digestivas e método de preparação e uso do mesmo | |
| JP2019516775A5 (https=) | ||
| Arboleya et al. | Assessment of intestinal microbiota modulation ability of Bifidobacterium strains in in vitro fecal batch cultures from preterm neonates | |
| Hong et al. | Evaluation of prebiotic effects of high-purity galactooligosaccharides in vitro and in vivo | |
| US11617772B2 (en) | Nutritional supplements and therapeutic compositions comprising probiotics | |
| Jin et al. | Engineered bacteria for disease diagnosis and treatment using synthetic biology | |
| Oddi et al. | Breast-milk derived potential probiotics as strategy for the management of childhood obesity | |
| RU2017121227A (ru) | Пробиотические штаммы, обладающие способностью поглощать холестерин, способы и их применение | |
| Kitazawa et al. | Probiotics: immunobiotics and immunogenics | |
| Arboleya et al. | In vitro evaluation of the impact of human background microbiota on the response to Bifidobacterium strains and fructo-oligosaccharides | |
| Lee et al. | A comprehensive review of synbiotics: an emerging paradigm in health promotion and disease management | |
| CN105124333A (zh) | 一种含益生菌组合物及其制备方法和应用 | |
| Panesar et al. | Probiotics, prebiotics and synbiotics: opportunities, health benefits and industrial challenges | |
| Huang et al. | Osteopontin associated Bifidobacterium bifidum microencapsulation modulates infant fecal fermentation and gut microbiota development | |
| DIET | Probiotics and Antimicrobial Proteins | |
| Jang et al. | Insight into microbial extracellular vesicles as key communication materials and their clinical implications for lung cancer | |
| Zacarías et al. | Safety, functional properties and technological performance in whey-based media of probiotic candidates from human breast milk | |
| Basholli-Salihu et al. | Prebiotics as excipients for enhancement of stability and functionality of Bifidobacterium longum ssp. infantis with potential application as symbiotics in food and pharmaceuticals | |
| JPWO2020236979A5 (https=) | ||
| WO2025094769A1 (ja) | プロバイオティクス又はプレバイオティクスのスクリーニング方法及びそれに用いるスクリーニング用培地 | |
| Kavas et al. | Determination of probiotic characteristics and resistance to biological barriers under in vitro gastrointestinal conditions in goat cheese produced using microencapsulated probiotic bacteria | |
| MY195544A (en) | Composition for Promoting Glucolipid Metabolism, and Preparation and Application Thereof | |
| EP3845632A1 (en) | Composition for promoting the growth of lactic acid bacteria comprising growth factors | |
| De Giani et al. | Positive modulation of a new reconstructed human gut microbiota by Maitake extract helpfully boosts the intestinal environment in vitro | |
| Ryšávka et al. | Targeted Modulation of Gut Microbiota by Personalized Probiotics. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |